ATP Citrate Lyase

ATP Citrate Lyase

ATP-citrate lyase (ACLY) is a central metabolic enzyme and catalyses the ATP-dependent conversion of citrate and coenzyme A (CoA) to oxaloacetate and acetyl-CoA.The biosynthesis of cholesterol, the metabolism of fatty acids, and the acetylation and prenylation of proteins all depend on the acetyl-CoA product. Additionally, acetylation reactions that alter proteins, like the acetylation of histones, require acetyl CoA. Multiple cancer types exhibit upregulation or activation of ACLY, and it is known that blocking ACLY results in both in vitro and in vivo proliferation arrest of cancer cells.

By catalyzing the creation of acetyl-CoA and oxaloacetate from citrate produced by glycolysis in the presence of ATP and CoA, ACLY connects the metabolism of glucose and lipids. In many immortalized cells and tumors, including breast, liver, colon, lung, and prostate cancers, ACLY is aberrantly expressed and negatively correlated with tumor stage and differentiation, making it a poor prognostic indicator. Acetyl-CoA is a crucial component of the synthesis of long chain fatty acids and is provided by ACLY, an enzyme that is upstream in the process. ACLY is a crucial enzyme in cellular lipogenesis and a powerful target for cancer treatment as a result.

ATP Citrate Lyase related products

Structure Cat No. Product Name CAS No. Product Description
V2839 BMS 303141 943962-47-8 BMS-303141 (BMS303141) is a novel, potent, cell-permeable ATP-citrate lyase (ACL) inhibitor with lipid-lowering effects.
V73921 Forrestiacids K 2920898-65-1
V73920 ForrestiacidsJ 2920898-66-2
V2147 NDI-091143 2375840-87-0 NDI-091143 (NDI091143) is a novel and potent inhibitor of human ATP-citrate lyase (ACLY) with anticancer activity.
V4609 SB-204990 154566-12-8 SB 204990, the prodrug of the ATP citrate-lyase inhibitor SB-201076, is a potent,orally available and specific inhibitor of ATP citrate lyase(ACLY)enzyme.
Contact Us